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Background: Venous malformations (VMs) are congenital vascular anomalies 
resulting from local defects in the vascular morphogenesis during fetal development. 
They cause highly variable symptoms and are associated with blood coagulation 
disorders. The treatment of VMs aims to alleviate symptoms, disfigurement, and blood 
coagulopathy. The current treatment strategies, including conservative treatment, 
sclerotherapy, surgery and laser ablation, all have different benefits and risk profiles. 
Sclerotherapy has recently become the primary treatment for most VMs. Sclerotherapy 
is, however, not without complications and some VMs seem refractory to it.  
Aims: This thesis aimed to investigate histology and imaging findings of VMs operated 
on for unsatisfactory sclerotherapy response (I), blood coagulation and fibrinolysis 
activity in pediatric VM patients (II), and safety aspects of sclerotherapy for trunk and 
extremity (III) and head and neck (IV) VMs. 
Patients and methods: In Studies I, III, and IV we included all consecutive VM 
patients who underwent sclerotherapy at Helsinki University Hospital between 2007 
and 2013. We analyzed histology and imaging findings of extremity VMs operated on 
for poor response to sclerotherapy (n=102) (I) and sclerotherapy complications of all 
sclerotherapy-treated patients (n=202) (III, IV). In Study II we included pediatric VM 
patients with detailed laboratory results for blood coagulation and fibrinolysis activity 
at a steady clinical phase (n=62).  We analyzed patients’ coagulation status and 
correlations of abnormal coagulation biomarkers to clinical and imaging findings. 
Results: Of the sclerotherapy-treated extremity VMs, 19 (19%) were operated on for 
insufficient sclerotherapy response. The number of intramuscular lower extremity 
lesions among operated VMs was 15. The histology of 13 of the 15 intramuscular VMs 
was not consistent with common VM, corresponding instead to angiomatosis of soft 
tissue (AST) (I). The imaging findings for common VMs and ASTs were overlapping 
(I). Pediatric VM patients had significant abnormalities in leukocyte levels and 
antithrombin, FVII, FVIII, and FXIII activities (II), in addition to previously reported 
commonly elevated D-dimer levels. Disseminated intravascular coagulation did not 
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occur and platelets were generally normal (II). The sclerotherapy complication rate per 
procedure was 13% for trunk and extremity VMs (III) and 10% for head and neck VMs 
(IV). Superficial location and use of ethanol increased the risk for local conservatively 
manageable complications (III). Severe complications, for which blood coagulopathy 
was a significant predisposing factor, occurred in seven procedures (1.6%) (III, IV).  
Conclusions: Histology has an important role in the differential diagnostics of 
intramuscular VMs, as different histological entities require different treatment 
approaches (I). VMs are associated with a number of specific abnormalities in 
coagulation biomarkers, implying a close interrelation between coagulation and 
angiogenesis (II). Sclerotherapy for both peripheral and head and neck VMs is 
generally safe, but entails a risk for severe complications (III, IV). 
Key words: angiomatosis of soft tissue, coagulopathy, complication, differential 
diagnostics, histology, interventional radiology, safety, sclerotherapy, surgery, vascular 





The term ‘vascular anomaly’ refers to a wide spectrum of congenital malformations and 
tumors of vascular origin ranging from inconsequential birthmarks to life-threatening 
and severely disfiguring conditions. Throughout most of the recorded history, they have 
been believed to result from the emotions, thoughts, or desires of the expectant mother. 
In the mid-19th century, Scottish anatomist William Hunter questioned this theory of 
“maternal impression” and introduced the concept of vascular anomaly [1,2]. However, 
lack of systematic categorization of these diverse lesions held back medical progress for 
over a century. While mothers were no longer blamed, the limited diagnostic 
knowledge often led to inappropriate management and unnecessary anxiety.  
In 1982, Mulliken and Glowacki studied the cellular characteristics of vascular 
anomalies and consequently divided them into vascular tumors and vascular 
malformations [3,4]. This division is still the basis for the current classification (ISSVA 
2014 [5]) comprising a detailed taxonomy for dozens of different vascular entities. 
This thesis focuses on venous malformations (VMs), which are the most common 
vascular malformations, giving rise to numerous consultations with interdisciplinary 
vascular anomaly teams [6,7]. VMs have highly variable clinical appearance and 
associations with the blood coagulation system [8]. Development of modern imaging 
modalities, radiological interventions, surgical techniques, and medications has 
essentially improved the management of VMs over the last two decades.  
Lack of familiarity with the terminology and differential diagnostics nevertheless leads 
to confusion and even mismanagement of VM patients. The most common misnomer is 
‘hemangioma’, which is incorrectly used in over 70% of publications concerning 
vascular anomalies [9].  ‘Hemangioma’ actually refers to endothelial tumors with 
cellular mitoses and proliferation [10] (Figure 1). VMs, instead, are structural 
anomalies with normal endothelial cell turnover [5,10]. The terms cavernous 
hemangioma (adult liver), venous hemangioma (soft tissue), and hemangioma of the 
bone (vertebra) should be abandoned as outdated and confusing, as these entities are 
histologically consistent with VMs [11-13].  
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Figure 1. Venous malformations (VMs) (A) are often confused with hemangiomas, of 
which infantile hemangioma (B) predominates and occurs only in children. When 
superficial, VM is bluish, soft, and compressible, whereas infantile hemangioma is 
relatively firm with a strawberry-like reddish appearance. 
 
The classification of vascular anomalies is evolving as new entities are recognized and 
knowledge about their pathophysiology and genetics is refined. This continuous 
development challenges the clinical strategies in the treatment of VMs. The current 
treatment modalities for VMs, including medical therapy, surgery, laser, and 
sclerotherapy, are applied with good overall results [14]. Some VMs remain, however, 
challenging to manage. Studying their specific features may reveal obscure aspects in 
differential diagnostics and blood coagulation disorders and facilitate the selection of 
the optimal treatment for each VM patient. 
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2. Review of the literature 
 
2.1 Classification of vascular anomalies 
The classification of vascular anomalies aims to unify and clarify the complex 
terminology used by multidisciplinary professionals. Accurate terminology is crucial 
for achieving the right diagnosis, and thereby, proper management [9,15]. The first 
classification based on endothelial characteristics of the vascular anomalies was 
introduced by Mulliken and Glowacki in 1982 [4]. It has since been revised and 
expanded by the International Society for the Study of Vascular Anomalies (ISSVA) to 
include the latest knowledge about genetics and clinical associations [5,16]. The 
essential framework of the ISSVA classification is the division of vascular anomalies 
into congenital malformations and proliferative tumors [5,17] (Figure 2).  
 
 
Figure 2. Outline of the current ISSVA classification of vascular anomalies [5].  
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Vascular malformations are structural defects resulting from local disturbances in the 
fetal vascular morphogenesis. Their further categorization is based on their 
predominant vessel type or combinations of different vessel types, as well as 
associations with other anomalies (Figure 2) [18]. Moreover, vascular malformations 
are often divided into low-flow and high-flow lesions for the clinical relevance of their 
pressure conditions (Figure 2) [19,20]. Vascular tumors, in turn, are proliferative 
lesions with mitotic activity [4]. They are divided into benign, borderline or locally 
aggressive, and malignant tumors according to their clinical behavior (Figure 2). 
Infantile hemangioma is the most common vascular tumor and also the most common 
pediatric tumor, affecting 4-10% of all children [1,21].  It has a unique clinical course 
of early proliferation and spontaneous involution (Figure 3). Congenital hemangioma, 
tufted angioma and kaposiform hemangioendothelioma are examples of rare vascular 
tumors with clinical course different from infantile hemangioma [22,23] (Figure 2).  
 
 
Figure 3. Natural course of a nasal tip infantile hemangioma; early proliferative phase 
after birth is followed by spontaneous involution by school age. During the involution 
the vascular component gradually diminishes ending up as a fibro-fatty residual with 
some excessive skin.  
 
2.2 Venous malformation 
2.2.1 Definition  
Venous malformations (VMs) are congenital structural defects of the postcapillary 
vessels with low-flow conditions [24,25]. They are typically local and singular lesions 
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affecting a restricted area of the body, but may also occur as segmental or multifocal 
(Figure 4). The anomalous veins may form local clusters or infiltrate diffusely any 
tissue or organ. They may be located superficially in subcutaneous fat or invade deep 
tissues such as muscle, bone or viscera [26].  
 
 
Figure 4. Clinical appearance of VMs varies depending on the location, size, depth, 
and morphology of the lesion. While some VMs are totally asymptomatic, others with 
critical locations or bulky structures may cause severe functional impairment and 
disfigurement. Extremity VMs typically induce pain and swelling provoked by physical 
activity. 
 
2.2.2 Genetics  
The vast majority of VMs occur sporadically, with inherited disease forms comprising 
only 1-6% [27]. The sporadic VMs are mostly isolated or segmental malformations, 
whereas the familial forms typically consist of multifocal lesions [28,29]. The causative 
gene for the sporadic VMs in most cases is TEK, which encodes the endothelial cell 
tyrosine receptor kinase 2 (TIE2) [29-31]. It binds angiopoietins and participates 
essentially in angiogenesis regulation and vessel wall stability maintenance through the 
PI3K/AKT signaling pathway [30]. The second most common causative gene, 
PIK3CA, is found in 20% of the VMs and influences the same PI3K/AKT pathway as 
 16
TEK [32]. In addition to the common VM, the rare blue rubber bleb nevus syndrome 
(BRBNS) also occurs sporadically. BRBNS patients have TIE2 mutations as well, but 
they appear characteristically in double in the same allele [27,33,34].  
Two different familial forms of VMs have been identified, the more common 
cutaneomucosal VM (VMCM) and the rare glomuvenous malformation (GVM) [27]. 
Both are inherited with an autosomal paradominant pattern, necessitating a second hit 
mutation for lesion formation [27]. In VMCM the primary mutation is again in 
TEK/TIE2, but distinct from the mutation in the sporadic VM [28]. GVM in turn, is 
caused by a loss-of-function mutation in the glomulin gene, which is obviously an 
integral player in the regulation of angiogenesis, especially vascular smooth-muscle 
development [27,35,36].  
2.2.3 Clinical presentations 
The estimated prevalence of VMs is approximately 1% [37,38]. As congenital, they are 
present at birth, but mostly become clinically apparent later in childhood [37,39]. They 
have a tendency to expand commensurate to the child’s growth, but they never spread 
into new body areas or regress spontaneously. Hormonal stimulus during puberty or 
pregnancy typically aggravates their growth (Figure 5) [39].  
Clinically, VMs are soft, compressible, and bluish when located superficially. Deeper 
lesions may manifest in asymmetry or pain, or may be discovered as incidental findings 
in imaging studies [40,41].  
The most common symptoms are pain and swelling, often provoked by physical 
activity through enhanced circulation and distension. Local thrombosis in the 
malformation is a common cause of pain. VMs may also cause severe disfigurement, 
cosmetic harm, functional impairment, or systemic complications through blood 





Figure 5. A series of pictures demonstrating the commensurate and slow expansion of a 
leg VM. The bluish discoloration and superficial nodules become more visible over 
time, but do not invade new areas. The natural course of VM essentially differs from 
that of infantile hemangioma (Figure 3). 
 
2.2.4 Imaging 
Imaging, especially ultrasonography (US) and magnetic resonance imaging (MRI), 
plays a central role in the evaluation of soft tissue lesions. US is often the first-line 
modality because of its good availability and usability without sedation even for small 
children [43]. In US, VMs appear as low-echogenicity, compressible, tubular structures 
that may invade subcutaneous fat or deeper tissues (Figure 6) [44]. The use of a 
tourniquet or standing position may facilitate their visualization as distension of the 
veins increases. The small field of view and restricted penetrance limits the 
applicability of US in extensive and deep lesions [24,43,45]. 
MRI complements the primary evaluation with US by elucidating the dimensions of the 
malformation, affected tissue planes, and relations to surrounding structures (Figure 7) 
[37,43,47].  
A typical VM presents high signal intensity in T2-weighted and low to intermediate 
signal in T1-weighted sequences (Figure 7). It may consist of either densely packed, 
well-demarcated tubular structures or rather diffusely infiltrating phlebectasia [43]. The 
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contrast enhancement varies from early and avid to partial and slow and differentiates 




Figure 6. Characteristic US features of VMs. A. Intramuscular low-echogenicity 
tubular structures that are compressible upon pressing the US probe. B. Phleboliths 
emerge as small hyperechoic foci with shadowing. C. Thrombosis in the venous 
channels appears as heterogeneous echogenic mass, which reduces the compressibility 
of the vascular channels. D.  The slow monophasic blood flow is mostly detectable with 
Color Doppler examination. Lack of detectable flow may be due to very slow velocity 
or thrombosis. E. Biphasic low-resistance flow indicates arteriovenous shunting not 






Figure 7. Axial MRI of a VM in the left flank clearly delineates the width of the lesion 
and relations to surrounding anatomy. A. T2-weighted fat-saturated image shows a high 
signal intensity lesion consisting of cluster-like tubular structures and low signal 
intensity thrombi. B. The signal in T1 is isointense with or slightly higher than 
surrounding muscles. C. Post-contrast T1 image demonstrates partial enhancement of 
the vascular channels.  
 
 
Figure 8. Coronal MRI of a neck lymphatic malformation. A. T2-weighted fat-
saturated image shows the wide fluid-filled vascular spaces surrounded by thin walls 
and septa. B. T1-weighted fat-saturated post-contrast image demonstrates the lack of 
internal enhancement of the vascular spaces. Some faint delineation of the wall 
structures is, however, detectable.  
 
A B C 
B A 
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Additional important differential diagnoses for VMs are the high-flow lesions, i.e. 
arteriovenous malformations (AVMs) and fistulas (AVFs). Their differentiation from 
VMs is crucial because of vastly different management strategies [1,49]. Flow void 
artifacts (Figure 9A) are characteristic for high-flow lesions and readily detectable in 
T1- and T2-weighted sequences [50]. Contrast-enhanced dynamic MRI (cedMRI) 
techniques reveal the flow dynamics in more detail and together with MRI have 
replaced conventional angiography in basic diagnostics (Figure 9B) [50-52].  
Despite being slow-flow lesions, VMs commonly enhance readily at arterial or early 
venous phase, causing confusion among radiologists not familiar with vascular 
malformations. However, tortuous feeding arteries and early enhancing draining veins, 
characteristic for AVMs, are absent in VMs. 
 
 
Figure 9. A. AVM of the hand with prominent flow voids indicating high-flow vessels. 
B. An arterial phase contrast-enhanced dynami MRI (cedMRI) points out an AVM of 
the right thigh revealing the anomalous feeding arteries and early enhancing draining 
veins. 
 
X-rays and computed tomography (CT), although revealing possible phleboliths, are 
mostly unnecessary in VM diagnostics (Figure 10) [53,54]. However, in rare cases of 
A B 
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Figure 10. Phleboliths, readily visible in x-ray images, are calcified nodules originating 
from organizing thrombi in venous spaces. They are typical for VMs but are not present 
in all cases. 
 
2.2.5 Histopathology 
In typical cases, histology is not necessary for VM diagnosis. However, when the 
findings of patient history and clinical examination do not match imaging results, 
biopsy is mandatory to exclude malignancy and to achieve the correct diagnosis 
[45,55].  
The histology of VMs consists of dilated and irregular venous-type channels that vary 
in size and form interconnecting networks among normal tissues (Figure 11) [12,56]. 
The wall structures of the anomalous veins are abnormally thin with a continuous flat 
endothelium but an irregular smooth muscle layer. Thrombosis is commonly present 
and it may organize to form fibromyxoid nodules or calcified phleboliths [57]. Specific 
immunohistochemical markers are used to reveal the abundant endothelium (CD31) and 
smooth muscle and pericytes (smooth-muscle actin (SMA)) (Figure 11). Podoplanin 
(D2-40), which is specific for lymphatic endothelium, stays negative in VMs, 
differentiating them from lymphatic malformations [12,58].  
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Figure 11. Typical histological features of VMs. A. Hematoxylin and Eosin staining of 
an intramuscular VM depicts the labyrinth-like interconnecting networks of venous 
channels. B. Smooth muscle actin staining demonstrates the irregularity of the smooth 
muscle layer in anomalous veins. C. CD31 staining highlights the endothelium of all 
vascular channels. The intraluminal thrombi also stain because CD31 is expressed in 
platelets in addition to endothelial cells.  
 
2.2.6 Differential diagnostics of intramuscular vascular malformations; AST, 
FAVA, and PHOST 
Intramuscular VMs comprise a challenging group of lesions in terms of differential 
diagnostics and management [45,59-61]. These lesions often cause chronic pain and 
significant functional impairment. The response to sclerotherapy is variable, but often 
insufficient, necessitating repeated procedures and surgical resections.  A growing body 
of evidence implies the presence of several distinct intramuscular vascular entities such 
as angiomatosis of soft tissue (AST), PTEN hamartoma of soft tissue (PHOST), and 
fibro-adipose vascular anomaly (FAVA). Because they present imaging features 
characteristic of slow-flow vascular malformations, they are easily mixed with VMs, 
but have specific histology and clinical behavior [45,59-62].  
Rao and Weiss described already in 1992 a benign vascular lesion termed angiomatosis 
of soft tissue (AST) [62]. They delineated its histology as consisting of various size 




intramuscular fat. They assumed these lesions to be of generalized mesenchymal origin 
rather than pure vascular malformations and reported high recurrence rates after 
surgical resections [62]. Wassef described this same lesion in more histological detail in 
2011 [61] and it has since been added to the new ISSVA classification (2014) under 
‘provisionally unclassified vascular anomalies’ [5,61]. He pointed out the marked 
irregularities in the vessel walls; the smooth muscle in the dilated veins varies from 
thick to tenuous with sudden clefts, whereas the walls of the arteries are often 
hyperplastic, narrowing the lumens. Honeycomb-like thin-walled vascular spaces, 
disorganized smooth muscle, lymphatic vessels, and lymphocyte nodules are 
characteristically present as well [61]. 
PHOST, in turn, is a distinct type of intramuscular vascular lesion encountered in 
patients with PTEN hamartoma tumor syndrome (PHTS) [60]. Its histology closely 
resembles that of ASTs, also consisting of vessel proliferations of different calibers, 
clusters of capillaries, increased intramuscular fat, and fibrous tissue. However, 
PHOSTs may additionally include AV shunts, a feature not reported for ASTs [58,60].  
Fibro-adipose vascular anomaly (FAVA), not described until 2014 by Alomari et al. 
[59], again shares many of the histological features characteristic for AST and PHOST. 
It is an intramuscular vascular lesion affecting primarily the lower limbs and is 
associated with muscle contractures and severe pain [59]. Alomari et al delineated the 
histology of 18 lesions, half of which were core needle specimens and the other half 
surgical specimens. The histological findings described were variable, including a 
dense fibro-fatty component, irregularly muscularized veins, lymphatic channels, thin-
walled vascular spaces mimicking pulmonary alveoli, lymphocyte aggregates, 
thrombosis, and phleboliths. They did not report any AV shunts or abnormal arteries 
[59]. 
The MRI findings for common intramuscular VM, PHOST, and FAVA overlap 
[43,59,60], whereas those for AST are not previously described. VM, PHOST, and 
FAVA all appear as predominantly intramuscular lesions with high signal intensity 
tubular structures in T2 sequences. The T2 signal intensity is, however, typically more 
heterogeneous in FAVA and PHOST than in common VMs [59,60]. Intramuscular fat, 
appearing as high signal intensity areas in T1, is often especially abundant in PHOST 
 24
and FAVA, but may appear in common VM as well. Neither the T1 enhancement 
pattern after gadolinium nor the presence of phleboliths conclusively distinguishes 
these lesions from each other [45,59,60].  
2.2.7 Blood coagulopathy 
VMs are associated with blood coagulation disorders in the form of elevated D-dimer in 
33-62% of patients [63-66]. This condition, designated as localized intravascular 
coagulopathy (LIC), may be an incidental finding in screening laboratory analyses or 
manifest as local thrombosis and subsequent pain. Elevated D-dimer correlates with 
larger lesion sizes, visceral and muscle involvement, and the presence of phleboliths 
[64,67]. LIC also entails a risk of progression to disseminated intravascular coagulation 
(DIC) as a consequence of intrinsic or extrinsic stimulus such as any invasive procedure 
or infection [68]. In DIC, the fibrinogen is concomitantly decreased and prothrombin 
time may be prolonged due to increased consumption of coagulation factors 
[8,63,64,69-73]. LIC and its exacerbation predisposes patients to potentially severe 
thrombosis and bleeding complications [71,72,74]. The pathophysiology behind the 
coagulopathy remains somewhat unresolved. According to the theory of LIC, a constant 
coagulation and subsequent fibrinolysis takes place in the dilated venous channels, 
leading to excessive consumption of fibrinogen and other coagulation factors. The slow 
flow conditions, stagnation of blood, and abnormal endothelium are possible 
contributing factors [75]. However, the lack of systematic reports on fibrinolysis and 
coagulation activity, bleeding times, and thrombophilias in VM patients weakens these 
speculations.  
The VM-related coagulopathy is different from the Kasabach-Merritt phenomenon, a 
condition encountered in association with rare pediatric vascular tumors such as 
kaposiform hemangioendothelioma and tufted angioma [76,77].  In Kasabach-Merritt 
phenomenon, platelets are trapped in the vascular tumor leading to potentially severe 
thrombocytopenia and bleeding diathesis, whereas in VM-related LIC the platelet count 
remains normal or only slightly decreased, but fibrin turnover and consumption of 
coagulation factors are increased. Thus, the etiology, treatment, and prognosis of these 
two conditions are completely different and they should not be confused.  
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The management of LIC in VM patients aims to reduce the VM size and blood 
stagnation [65,75]. The use of graded compression garments on extremity 
malformations diminishes the distention of the venous spaces, reducing swelling, pain, 
and functional impairment. It probably also alleviates the LIC, although this has not 
been systematically studied [65,75]. Invasive procedures, such as sclerotherapy, 
surgery, and laser ablation, all aim to reduce the mass of the malformation, but 
conversely may serve as triggers for exacerbation of LIC [78]. Anticoagulation therapy 
in the form of low-molecular-weight heparin (LMWH) has proven effective in 
diminishing thrombosis and pain episodes and in normalizing D-dimer and fibrinogen 
levels [63,76].    
2.2.8 Treatment 
VMs require individually tailored treatment strategies because of the highly variable 
clinical picture. An interdisciplinary approach in the form of regular patient meetings is 
pivotal in achieving proper diagnostics and optimal treatment for each patient [79,80]. 
Since curative management is rarely available, the aim is to alleviate symptoms and 
relieve cosmetic disfigurement. The current main treatment options for VMs include 
conservative treatment, sclerotherapy, surgery, laser ablation, and pharmacological 
treatment [25,81,82]. The literature on treatment outcomes lacks uniform and reliable 
methods for the evaluation of subjective symptoms and functional impairment, 
hindering the comparison between different modalities [14,83-90].  
2.2.8.1 Conservative treatment 
After proper diagnostics and counseling, asymptomatic VM patients do not necessarily 
need any treatment. Children and adolescents should, however, be followed up for the 
progression tendency of VMs [10,39]. Graded compression garments are suitable as the 
only treatment for extremity VMs with mild symptoms, or combined with any invasive 
treatment for more symptomatic patients [37,49,82,91]. They seem to alleviate 
symptoms and functional impairment, probably by reducing blood volume and 
distension of the malformation and forcing the blood into the deep venous system. The 
garments must be individually tailored to provide optimal support and used preferably 
during the daytime or at least when physically active.  
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2.2.8.2 Sclerotherapy 
Sclerotherapy is currently the primary treatment for most symptomatic VMs 
[19,25,92,93]. It is less invasive than surgery and also applicable for lesions considered 
non-resectable. On the other hand, repeated sessions are commonly required to achieve 
satisfactory response [19,94].  
The aim of sclerotherapy is to shrink and obliterate the malformation by permanently 
closing the anomalous vessels. The locally injected sclerosing agent induces endothelial 
cell damage followed by inflammatory response, fibrobroblast proliferation, and 
sclerosis [95]. The mechanism of action depends on the type of sclerosant used and is 
not exactly understood. The influence may be chemical, physical, and/or biologic [95]. 
Thrombosis, cell dehydration by osmosis, and extraction of proteins from lipids are 
contributing factors in the disruption of biologic function of the targeted endothelium 
[95]. Understanding the nature of the malformation, properties of the sclerosants in use, 
delivery methods, optimal concentrations, effects of flow, and potential side effects is 
essential for success of the treatment. 
The sclerosing agent is injected percutaneously into the vessel lumens using US and 
fluoroscopy guidance. A prior contrast injection is necessary to estimate the volume of 
the lesion and to determine the routes of the draining veins. Intravenous access is 
confirmed by venous back-flow from the inserted needle. A tourniquet or manual 
compression of the draining veins minimizes the risk for systemic escape of the 
sclerosant. Usage of the draining technique, in which two or several needles are placed 
in different parts of the malformation, one for injecting the sclerosant and the others for 
draining the blood and excessive sclerosant, helps to avoid overfilling the lesion and 
ensures flushing the whole VM with the sclerosant  (Figure 12) [19,37]. 
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Figure 12. Fluoroscopy image of a sclerotherapy procedure with the draining 
technique. Several needles are placed in the VM to ensure the escape of excessive 
sclerosant and to prevent overfilling of the lesion. 
 
The most commonly used sclerosing agents for VMs include ethanol, sodium tetradecyl 
sulphate (STS), polidocanol, and bleomysin.  They are all applicable and differ mainly 
by their effectiveness and risk profiles [14,19,84,96-98]. Ethanol is the most effective 
sclerosant due to its high toxicity and ability to cause instant endothelial damage. Its 
usage has diminished because of the common adverse effects, such as postprocedural 
pain and swelling as well as the high complication rates [19,88,99-104]. The detergent 
sclerosants, i.e. STS and polidocanol, are less potent but more versatile due to their 
capacity to form foam and their availability in different concentrations. The detergents 
induce less pain upon injection and the risk for complications is lower than with ethanol 
[105,106]. Bleomycin is commonly used for lymphatic malformations, but is applicable 
also for VMs. It is an antibiotic derivate, originally approved for oncologic use for its 
cytotoxic properties. Bleomycin has a lesser tendency to cause swelling and is thus 
especially suitable for anatomically confined and delicate locations [88].  
Ethylcellulose-ethanol is a newly developed agent in which ethanol is combined with 
rapidly forming ethylcellulose gel. This gel framework prevents ethanol from escaping 
the target vessel thereby increasing the local influence to the endothelium and 
diminishing adverse effects [107] [107].  
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2.2.8.3 Additional endovascular techniques 
Additional endovascular techniques, such as gluing and coiling, can be combined with 
percutaneous sclerotherapy in selected cases [19]. Closing large draining veins with 
intravascular coils is practical when manual compression or use of tourniquet is not 
sufficient. Glue may be used for closing especially wide venous spaces or anomalous 
truncular veins.   
2.2.8.4 Sclerotherapy complications 
Despite the mini-invasive nature of sclerotherapy, both local and systemic 
complications may occur. The most common complications include local skin 
blistering, intensification of pain and swelling, neural paresthesia, and skin 
discoloration [83,92,94,108-115]. Possible systemic complications include 
hemoglobinuria, affecting up to 34% of patients after sclerotherapy, and accompanied 
by transient oliguria in 57% of cases[116]. Paradoxical gas embolism and subsequent 
stroke is a very rare but potential complication of foam sclerotherapy [117,118]. A 
right-to-left heart shunt, especially patent foramen ovale, is the most common 
predisposing factor [118]. The risk for paradoxical embolism can be diminished by 
preparing the foam with CO2 instead of air. Single case reports cover extensive muscle 
necrosis and infection following ethanol and STS sclerotherapy [99], pulmonary 
embolism [119], and reversible and fatal cardiovascular collapse after polidocanol and 
ethanol sclerotherapy, respectively [100,120]. In each individual case, the complication 
risk must be weighed against the expected benefits and discussed with the patient 
beforehand.     
2.2.8.5 Surgery 
Since the development of sclerotherapy techniques, the role of surgery has diminished. 
It still, however, remains an important modality for selected cases [86,121]. For 
example, completely clotted VMs with persisting symptoms, symptomatic 
glomuvenous malformations, intramuscular FAVA lesions not responding to 
conservative treatment, and well-demarcated VMs of the palm and hand may benefit 
from primary surgical excision. Moreover, patients with intra-articular VMs, especially 
affecting the knee joint, benefit from surgical treatment [122]. Recurrent hemarthroses 
and subsequent cartilage damage can be avoided by early synovectomy. In addition, 
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patients with poor response to sclerotherapy may benefit from secondary surgical 
resections (Figure 13) [86]. Adjunctive sclerotherapy is considered applicable in cases 
of large malformations to reduce their size and extent before resection [123,124]. 
Preoperative glue embolization with percutaneously injected n–butyl cyanoacrylate (n-
BCA) has been used successfully for the treatment of facial VMs [125] 
 
 
Figure 13. Surgical excision of an intramuscular VM of the soleus muscle. The surgical 
strategies for VMs must be highly individualized and carefully planned with detailed 
imaging. Image courtesy of Erkki Tukiainen/Pia Vuola, HUH, Department of Plastic 
Surgery. 
 
2.2.8.6 Laser therapy 
Laser ablation has gained ground in the treatment of saphenous vein insufficiency and 
tributary varices [126]. It has since been applied for the treatment of infantile 
hemangiomas and vascular malformations, with promising results especially for VMs 
[14,90,127-130]. Several types of laser applications are in use, diode, CO2, and 
nd:YAG laser being the most common. The aim of laser therapy is to cause thermal 
damage directly to the endothelium, leading to vessel closure by fibrotic obliteration 
[126]. Laser ablation is regarded as mini-invasive without systemic influences. The 
most common complications include local skin blisters, pain, ecchymosis, and 
paresthesia [126]. Use of local tumescent anesthesia during the procedure diminishes 
the risk for complications [131]. Perivenously injected tumescent anestesia reduces 
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pain, protects surrounding tissues by cooling and insulating, and increases contact area 
between laser tip and endothelium through vasoconstriction [131,132]. In a series of 32 
patients with upper aerodigestive tract VMs, 980 nm diode endovenous laser proved 
effective in terms of reducing dysphagia and obstructive sleep apnea [90]. In another 
series of 164 peripheral VMs, the clinical success rates after endovascular diode laser 
treatment were 98% for reduction of pain and 69% for cosmetic outcome [126].   
2.2.8.7 Medical therapy 
Limited case series have described the efficacy of the mammalian target of rapamycin 
(mTOR) inhibitor, sirolimus, in the treatment of complicated vascular anomalies [133-
135]. The rationale behind these promising results is the key role of mTOR in the 
regulation of angiogenesis and development of vascular anomalies [33,136]. Sirolimus 
has proved especially promising in the treatment of complex lymphatic anomalies and 
lymphatic malformations as well as combined lymphatic-venous malformations [134]. 
Ongoing clinical trials will soon provide more data on the role of sirolimus in the 
management of complex venous malformations refractory to other treatments. 
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3. Aims of the study 
 
This thesis aimed to study histology and imaging in differential diagnostics of 
intramuscular VMs, blood coagulation disorders in pediatric VM patients, and safety 
aspects of sclerotherapy treatment for VMs. Specifically, the objectives of Studies I-IV 
were to investigate the following: 
1) Whether different histological entities are identifiable in the histological 
specimens of VMs operated on for poor sclerotherapy response, and whether 
they have any specific preoperative imaging findings (I). 
2) What specific findings children with VMs have in extended analysis of blood 
coagulation and fibrinolysis activity in the quiescent clinical phase, and how 
these correlate with VM’s clinical and imaging features (II).  
3) The complication rate of sclerotherapy for trunk and extremity VMs (III) and 
head and neck VMs (IV), together with possible predisposing factors for and 
measures to avoid sclerotherapy complications (III, IV).   
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4. Materials and methods 
 
4.1 Summary of methods (I-IV) 
 
4.1.1 Study design and ethical considerations 
This thesis was prepared in cooperation with the interdisciplinary team for vascular 
anomalies at Helsinki University Hospital (HUH). The team coordinates diagnostics, 
treatment, and follow-up for vascular anomaly patients in the HUH district of ca. 1.5 
million people as well as for referral patients from other university hospital districts in 
Finland. The team consists of specialists in interventional and pediatric radiology, 
neuroradiology, pediatric, plastic, vascular, and maxillofacial surgery, 
otorhinolaryngology, pathology, dermatology, ophthalmology, and hematology. In 
addition to the regular patient meetings, the team has an active scientific input.  
The institutional review board of HUH approved the study protocol. The study design 
was retrospective utilizing of patient records, imaging, and histological specimens.  
4.1.2 Patients 
The study populations in Studies I, III, and IV consisted of consecutive VM patients 
treated with sclerotherapy in HUH from 1 January 2007 to 31 August 2013. Study I 
included patients with extremity VMs (n=102), Study III patients with trunk and 
extremity VMs (n=127), and Study IV patients with head and neck VMs (n=75) (Table 
1). The HUH interdisciplinary team for vascular anomalies had evaluated the patients 
and recommended the treatment. The diagnosis of each patient was additionally 
confirmed from imaging studies (MRI, US, and periprocedural phlebography) 
according to the ISSVA classification (1996).  
The study population in Study II (n=62) was collected from the outpatient registry of 
the pediatric surgery clinic at Helsinki Children’s Hospital from 1 January 2002 to 31 
December 2015 (Table 1). Only patients with VMs and available complete laboratory 
results of blood coagulation activity, bleeding tendency, and blood cell count from one 
clinically stable time point were included.  
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In Study I, we evaluated the clinical records of 102 consecutive patients treated with 
sclerotherapy for extremity VM and identified those who had later been operated on for 
insufficient or poor sclerotherapy response (n=19). We analyzed the histological 
specimens of the operated patients with a semi-quantitative grading scale and 
concluded the histological diagnoses accordingly (Table 2). Finally, we qualitatively 
compared the histological diagnoses with the preoperative MR imaging by analyzing 
the morphology of the malformation, amount of fat tissue visible in T1-weighted 
sequences, presence of phleboliths, and enhancement patterns after gadolinium. 
 
Table 2. Histological features and their associations with different intramuscular 
vascular anomalies [17,59,61]. 
  
N (screened) Age median Male/Female VM location
Study I 19 (102) 21 40/62 extremity
Study II 62 12 27/35 all
Study III 127 22 54/73 trunk, extremity
Study IV 75 33 24/51 head, neck
VM, venous malformation
Histological features VM AST FAVA
Wide venous spaces +++ ++ +++
Honeycomb-like vessels - ++ +++
Lymphocyte clusters - +++ +
Thick-walled artery-like vessels - ++ -
Intramuscular fat + +++ +++
Fibrosis + +++ +++
Disorganized smooth muscle - +++ -
Phleboliths ++ + ++
Small vessel component + +++ +




In Study II, we systematically analyzed the laboratory results, including coagulation 
and fibrinolysis activity, coagulation times, thrombophilia markers, and blood cell 
counts, of 62 pediatric VM patients. All laboratory results were from one clinically 
stable time point. We analyzed correlations between abnormal laboratory variables and 
clinical and imaging findings of the patients and malformations, derived from patient 
records and MRI studies. We additionally recorded any anticoagulation therapies the 
patients had undergone, and all coagulopathy-related complications.  
In Studies III and IV, we retrospectively analyzed sclerotherapy-related complications 
of 202 VM patients undergoing a total of 280 peripheral and 150 head and neck 
sclerotherapy procedures. We graded the complications according to the Clavien–Dindo 
complication classification (Table 3). It is based on the management necessitated by 
complications, and has previously only been used for the reporting of surgical 
complications.  All post-procedural disabilities, except for transient pain or swelling 
lasting less than two weeks, were considered complications. Insufficient symptom relief 
was not regarded as a complication. We analyzed whether complications were 
associated with VM features (location and involved tissue planes) or treatment 
properties (the sclerosant used, number of treatments, or history of previous surgery) of 
peripheral (III) and head and neck (IV) VMs. 
 




Conservatively manageable complications without need for pharmacological treatment or surgical, 
endoscopic, or radiological interventions. Acceptable therapeutic regiments are: drugs as antiemetics, 
antipyretics, analgetics, diuretics, electrolytes, and physiotherapy.
 II Necessitating pharmacological treatment with drugs other than acceptable for grade I
 III Necessitating surgical, endoscopic, or radiological intervention
    IIIa Without general anesthesia
    IIIb With general anesthesia
 IV Life-threatening complication requiring intermediate care/intensive care-unit management
    IVa Single-organ dysfunction (incl. dialysis)
    IVb Multiorgan dysfunction
 V Death of patient
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4.1.4 Statistics 
Statistical analyses were conducted with Microsoft Excel 2011 and NCSS 8 statistical 
software. Chi-Square test or Fisher’s exact test and Mann-Whitney U-test served for 
paired comparisons. For correlation calculations we used Pearson’s correlation analysis 
and Spearman’s rank (non-parametric variables). We considered p-values < 0.05 to be 




5.1 Angiomatosis of soft tissue is an important differential diagnosis 
for intramuscular venous malformations (I) 
 
Of the 19 patients operated on for insufficient sclerotherapy response, 15 had an 
intramuscular lower extremity malformation. The histological diagnosis for 13/15 
intramuscular lower extremity lesions was angiomatosis of soft tissue (AST) or fibro-
adipose vascular anomaly (FAVA), while the remaining six operated lesions were 
compatible with common VMs (Table 2). AST and FAVA were not clearly 
distinguishable from each other based on histological picture (Table 2). Figure 14 
shows the most important histological features for AST. 
The MRI findings for common intramuscular VMs and ASTs were overlapping; both 
emerged as tubular structures with signal high in T2 and low to intermediate in T1 
sequences (Figure 15).  The internal enhancement after gadolinium and amount of 
intramuscular fat was variable in both. Phleboliths, commonly present in VMs, were 
occasionally present in ASTs as well. Fluid-fluid levels and cluster-like appearance 
were more characteristic for VMs, whereas heterogeneous T2 signal, visibility of small 
vessels in addition to dilated veins, and diffuse enhancement implied AST.  
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Figure 14. Histological features for AST. A. A wide venous space with markedly thick 
and irregular smooth muscle wall surrounded by intramuscular fat. B. Mature fat 
interspersed among muscle fibers C. Lymphocyte clusters, honeycomb-like vascular 
spaces, and fibrosis. D. Honeycomb-like vascular spaces filled here with erythrocytes, 
but commonly stained positive with podoplanin, specific for lymphatic endothelium. E. 
Clusters of small vessels. D. Elastic staining of thick-walled artery-like vessels 
demonstrating lack of elastin layer, characteristic for normal arteries, in their walls. 
 
 
Figure 15. T2-weighted fat-saturated MR images of different lower extremity AST 
lesions demonstrating overlapping imaging features with intramuscular VMs. 
A B C 
D E E 
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5.2 Venous malformations are associated with diverse abnormalities in 
the blood coagulation system in pediatric patients (II) 
 
Among the 62 evaluated pediatric VM patients overt DIC or thrombocytopenia did not 
occur and fibrinogen was normal in all but one patient. The prevalence of congenital 
thrombophilias did not differ from the general population. Substantial abnormalities 
were, however, detectable in leukocyte, antithrombin, coagulation factor (FVII, FVIII, 
and FXIII), and D-dimer levels (Table 4). D-dimer was elevated in 39%, indicating 
enhanced fibrin turnover. FVII and FXIII were decreased, whereas FVIII and 
antithrombin were elevated in one-fifth of patients. The elevation of D-dimer (p=0.07) 
and decrease of FXIII (p=0.03) were most common in the largest lesions (> 25 cm), in 
lesions spreading into multiple locations (p=0.01), and in cases with diffuse 
morphology (D-dimer p=0.02, FXIII p=0.21). FVIII, instead, was never elevated in the 
largest lesions or in lesions with deep locations. FVIII elevation was associated with 
discrete morphology (p=0.001) and less reported pain at time of initial evaluation 
(p=0.02). Antithrombin (elevated in 55%) and leukocytes (decreased in 33%) did not 
correlate with any of the clinical findings.  
Table 4. Coagulation profiles of the pediatric VM patients. 
 






limit         
N (%)
Values 
above the  
reference 
limit        
N (%)
Leukocytes (E9/L) 5-14 57 5.8 2.8-14.9 19 (33.3) 1 (1.8)
Platelets (E9/L) 200-450 58 267.0 172-619 6 (10.3) 1 (1.7)
Fibrinogen (g/L) 1.7-4 60 2.9 0.0-5.2 1 (1.7) 6 (10.0)
Prothrombin time (%) 70-130 62 94.5 66-157 4 (6.6) 4 (6.5)
APTT (s) 24-40 61 27.0 24-49 0 2 (3.3)
Thrombin time (s) 17-25 62 18.0 15-37 6 (9.7) 1 (1.6)
Antithrombin (%) 84-108 62 110.0 84-134 0 34 (54.8)
FV (%) 79-128 61 102.0 56-136 6 (9.8) 2 (3.3)
FVII (%) 76-170 59 90.0 48-222 12 (20.3) 1 (1.7)
FVIII (%) 52-148 62 119.5 75-206 0 11 (17.7)
FXIII (%) 76-156 60 95.5 53-148 12 (20.0) 0
Protein C (%) 74-141 61 91.0 65-173 3 (4.9) 3 (4.9)
Protein S Ag (%) 50-137 62 100.0 42-143 1 (1.6) 3 (4.8)
vWFRCo (%) 44-183 53 82.0 44-220 0 2 (3.8)
vWF-Ag (%) 51-169 58 89.5 50-187 1 (1.7) 1 (1.7)
D-dimer (mg/L) < 0.5 61 0.3 0.1-15 0 24 (39.3)
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5.3 Superficial lesion location, use of ethanol, and blood coagulopathy 
are associated with increased risk for sclerotherapy complications (III, 
IV) 
 
5.3.1 Sclerotherapy complications for trunk and extremity venous malformations 
(III) 
Complications occurred in 35 procedures for 31 patients, the complication rate per 
procedure being 12.5%. Most of the complications (83.3%) were local and 
conservatively manageable grade I-II complications, of which local skin damage and 
prolonged pain or swelling were the most common. Two skin wounds were managed 
with skin grafting, compatible with grade III complications (Figure 16).  In addition, 
four severe complications occurred: three grade IV and one fatal grade V complication. 
All patients suffering severe complications had blood coagulopathy with elevated D-
dimer and decreased fibrinogen level. Predisposing factors for local complications were 
superficial lesion location (p=0.049) and use of ethanol as a sclerosant (p=0.02). Use of 
STS vs. polidocanol, lesion location (extremity vs. trunk), previous surgery, number of 
procedures, or patient age were not associated with the occurrence of complications.  
 
 
Figure 16. A local complication after sclerotherapy with sodium tetradecyl sulphate 3% 
for a previously operated finger VM. A. T2-weighted fat-saturated MRI shows the 
subcutaneous malformation with intra-osseal component. B. Sclerosant’s local toxicity 
resulted in deep skin necrosis that was classified as a grade III complication due to need 
for surgical management. C. Three months after skin grafting.  
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5.3.2 Sclerotherapy complications for head and neck venous malformations (IV) 
Among the 75 head and neck VM patients who underwent 150 sclerotherapy 
procedures, the overall number of complications was 15, suffered by 13 patients. The 
complication rate per procedure was 10.0%. Twelve complications were treated 
conservatively (grade I and II), while three complications necessitated extensive and 
prolonged postprocedural management (grade III and IV). The patients with 
complications had a higher number of sclerotherapy procedures (p=0.009) and more 
commonly surgical treatment after sclerotherapy (p=0.007). The head and neck 
complications were not associated with the lesion location or depth or with the 
sclerosant used. Complications occurred, however, proportionally more often with 
bleomycin and when combining ethanol with other sclerosants.  
5.3.3 Severe sclerotherapy complications (III, IV) 
Although complications were, in most cases, local and healed with conservative 
management, severe complications, requiring extensive postprocedural management, 
occurred in seven sclerotherapy sessions (1.6%). The malformations in patients with 
severe complications were extensive or had challenging locations. The trunk or 
extremity VMs were additionally complicated by blood coagulopathy.  The 
mechanisms of severe complications remained partly obscure and these complications 
occurred despite careful preprocedural planning and treatment of the coagulation 
disorder in close cooperation with hematologists. The severe complications included: 
- Massive intra-abdominal bleeding resulting from sclerotherapy for extensive 
retroperitoneal VM. This complication was treated with intravascular 
embolization of the left phrenic artery, blood transfusions, and stabilization at 
the intensive care unit (III). 
- Two episodes of bleeding and infection of resulting hematoma, complicated by 
worsening of blood coagulopathy. These complications followed two separate 
procedures of sclerotherapy, laser, and gluing for an extensive pelvic and 
perirectal malformation. They were treated with intravenous antibiotics, blood 
and coagulation factor transfusions, and prolonged hospitalization (III). 
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- Fatal intracerebral bleeding after sclerotherapy for an extremely wide upper 
body malformation with severe coagulopathy (III). 
- Necrosis of maxilla and three teeth resulting from STS sclerotherapy for palate 
VM. This complication required surgical removal of necrotic tissue and caused 
permanent bone defect, allodynia, and infraorbital nerve defect (IV). 
- Extensive skin and muscle necrosis resulting from STS sclerotherapy for a 
frontotemporal VM. This complication required several surgical revisions, skin 
grafting and scar correction and caused permanent scarring and loss of function 
of the right frontal muscle (IV). 
- Extensive intraprocedural bleeding of a tongue VM managed with particle 
embolization, resulting in partial tongue muscle necrosis and infection. This 
complication treated with intravenous antibiotics and partial resection of the 





This thesis focuses on three different aspects of VMs: differential diagnostics of 
intramuscular VMs (I), blood coagulation in pediatric VM patients (II), and 
sclerotherapy safety for trunk and extremity (III) and head and neck (IV) VMs.  
AST was the predominant histological entity among intramuscular VMs operated on for 
unsatisfactory sclerotherapy response (I). Pediatric VM patients had diverse 
abnormalities in hemostatic markers that were associated with clinical and imaging 
findings of the VMs (II). The vast majority of sclerotherapy complications were local 
and conservatively manageable (III, IV). Local complications were associated with 
superficial lesion location and use of ethanol as a sclerosant (III). Blood coagulopathy 
was an important predisposing factor for the few severe complications (III). 
 
6.1 Differential diagnostics and selection of treatment for 
intramuscular venous malformations (I) 
 
Even though the differential diagnostics between VMs and other vascular anomalies is 
established in general, novel challenges emerge with the newly recognized vascular 
entities such as angiomatosis of soft tissue (AST), fibro-adipose vascular anomaly 
(FAVA), and PTEN hamartoma of soft tissue (PHOST). Distinction of these entities 
from common VMs seems to have clinical relevance for the differences in optimal 
treatment strategies [59-62]. While sclerotherapy is applicable for most VMs, it is 
obviously less effective for AST, PHOST, and FAVA because of their solid fibro-fatty 
tissue and vascular components not responsive to sclerosants [60,61].  
According to our study, histological features consistent with AST prevailed among 
lower extremity intramuscular lesions that were first diagnosed as VMs but later 
operated on for insufficient sclerotherapy response (I). These histological features, 
however, also closely resembled those previously described for FAVA and PHOST 
[59,60]. As FAVA and PHOST have both been described with limited patient numbers 
and in selected clinical contexts, they possibly all represent histologically the same 
entity with varying clinical manifestations. We termed these lesions as ASTs since AST 
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is the first designation in the literature for this histological entity and its definition is 
without specific descriptions of the clinical picture [62]. AST is also added to the 
current ISSVA classification under ‘provisionally unclassified vascular anomalies’ [5].  
Because we only had histological specimens of the surgically treated malformations 
that had not responded to sclerotherapy, the number of AST lesions treated successfully 
with sclerotherapy remains unknown. Therefore, definite conclusions about the optimal 
treatment for AST are not justified based on our study. Regarding the histological 
composition of AST and the high proportion of ASTs among operated lesions, our 
findings do, however, imply that sclerotherapy is not the primary treatment for these 
lesions (I). Even so, sclerotherapy may reduce the volume of AST lesions with 
prominent venous component, thereby alleviating the intramuscular pressure and 
distension. On the other hand, as very few common VMs necessitated secondary 
surgery, sclerotherapy seems to be effective for common VMs also in the intramuscular 
location (I).  
For these reasons, the pretreatment differentiation between common VMs and ASTs is 
important.  As we could not identify specific MRI findings for AST, we emphasize the 
role of histology in differential diagnostics (I). Obtaining adequate core needle biopsies 
from VMs and ASTs has, however, proved challenging as the specimen often impinges 
on a vessel wall and becomes fragmented and scarce. According to our experience, US 
may be helpful in differential diagnostics, revealing the small arteries of AST and 
demonstrating less compressibility with AST than with common VM. This has, 
however, not been systematically studied.  
 
6.2 Venous malformations and blood coagulation (II) 
 
Based on clinical observations and previous studies, the association between blood 
coagulation disorders and VMs is convincing. Several studies report elevated D-dimer 
and decreased fibrinogen in VM patients [8,64,67,69,76,137]. Blood coagulopathy also 
predisposes VM patients to severe complications, especially during invasive procedures 
[71,72,78].  
 44
Unlike the previous studies concentrating mainly on D-dimer and fibrinogen, we 
extended the analysis to cover detailed laboratory analysis of both coagulation and 
fibrinolysis activity as well as blood cell counts (BCC) (II). This enabled us to detect 
new and more diverse VM-related abnormalities in blood coagulation. Moreover, our 
unique study population comprising only children and timing of the blood sampling 
during a stable clinical phase presumably facilitated observation of VM-specific 
findings (II). 
D-dimer was elevated in 39% of our pediatric patients, compatible with previous 
studies [67,69], whereas overt DIC with hypofibrinogenemia and thrombocytopenia did 
not appear (II). Significant abnormalities appeared, however, in leukocyte (low), 
antithrombin (high), FVII (low), FVIII (high), and FXIII (low) levels. Moreover, FVIII, 
FXIII, and D-dimer were associated with clinical features of the malformations.  
The prevailing theory, designated as localized intravascular coagulation (LIC), explains 
the VM-related coagulopathy by constantly occurring local coagulation, excessive 
consumption of coagulation factors, and subsequently enhanced fibrin turnover [8,75].  
This theory, not applied for any other conditions, is based on findings in the peripheral 
blood and established without local blood sampling or detailed evaluation of the 
coagulation biomarkers.  
Our findings are not explained by the theory of LIC; the deficiencies in FVII and FXIII 
activities did not correlate with the elevation of D-dimer, decrease of fibrinogen, or 
other findings of enhanced consumption.  Furthermore, unlike in conditions with 
enhanced consumption, antithrombin and FVIII were commonly elevated. Although the 
general significance of elevated antithrombin is unclear, we assume that it protects VM 
patients against excessive coagulation activity. High FVIII level has previously been 
linked to increased risk for venous thrombosis [138]. However, in our study, patients 
with elevated FVIII had less local pain and thus presumably less thrombosis. FXIII, in 
turn, has a central role in the stabilization of fibrin clot [139]. Decreased FXIII activity, 
as in one-fifth of our patients, makes the clot more loose and susceptible to fibrinolysis, 
thereby increasing the fibrin turnover. Moreover, a recent study shows that specific 
effects of the VM causative TIE2 mutation lead to activation of the 
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plasminogen/plasmin protease system, also contributing to fibrin degradation in VM 
patients [30]. 
A growing body of evidence indicates close interrelation between coagulation and 
angiogenesis [30,33,140,141]. Also in our study, many of the coagulation biomarkers 
associated with VMs are active contributors to the regulation of vessel development and 
maintenance [30,140-142]. Better understanding of the mechanisms behind this co-
regulation will elucidate the pathophysiology of VMs and related coagulopathy. 
 
6.3 Sclerotherapy safety for venous malformations (III, IV) 
 
Regarded as mini-invasive and generally safe, sclerotherapy has become an essential 
treatment modality for VMs during the past decade. Systematic evaluation of 
complications of any treatment is, however, essential to improve the safety of the 
process and to gain tools for critical comparison of available treatment options. 
However, the definition of complication markedly differs between studies, hampering 
their comparison. For example, many studies do not report self-healing superficial skin 
blisters as complications or only report ‘major’ complications. Moreover, varying 
complication classifications, study populations, sclerotherapy procedures, and 
sclerosants make the complication rates uncomparable [83,94,97,115,143].   
To gain a more complete picture, we defined complication as any disability developing 
as a consequence of the treatment, including small skin wounds (III, IV). We also 
introduced the Clavien–Dindo classification (Table 2) [144,145] for the evaluation of 
sclerotherapy complications in order to improve accuracy and facilitate comparison 
with other reports (III, IV). Based on the management needed for the complication, the 
Clavien–Dindo classification is more objective and informative than the subjective 
division of complications into minor and major.  
We consider our complication rates, 10.0% for head and neck and 12.5% for trunk and 
extremity VMs, to be acceptable. Majority of the complications were local grade I-II 
complications, neither influencing treatment outcome nor patient satisfaction in most 
cases (III, IV). Grade I-II complications are often avoidable by careful sclerotherapy 
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technique and selection of appropriate sclerosant. Awareness of potentially very severe 
complications is important, especially when treating very extensive VMs or VMs in 
critical locations. Such complications occurred in 1.6% of the sclerotherapy procedures, 
blood coagulopathy being a significant predisposing factor. Despite careful preparation 
and skilled management, complications do occur. Interdisciplinary cooperation is 
pivotal not only in diagnostics and treatment planning but also in managing 
complications.  
Superficial lesion location predisposed to skin damage through the local toxicity of the 
sclerosant. This risk can be diminished, although not totally effaced, by using 
detergents with low concentrations. The efficacy of a sclerosant, however, more or less 
parallels its toxicity. Ethanol, for example, is the most potent sclerosant, but 
predisposes to both local tissue damage and severe systemic complications 
[99,101,102]. The use of ethanol was associated with the occurrence of complications 
also in our study, although utilized only in a limited number of cases at the beginning of 
the study period (IV). Ethylcellulose-ethanol is a new sclerosant with promising 
preliminary results [107,146]. It combines the efficacy of ethanol with a lower tendency 
to drain off the target place, thereby causing less complications.  
One important finding was the association between gluing and infections (IV). Glue 
was applied in a limited number of procedures in order to close wide venous spaces in 
which sclerotherapy alone was ineffective. As a foreign material it, however, offers 
together with stagnant blood a propitious bed for bacterial growth. We have since 
started to use antibiotic prophylaxis when combining gluing with VM sclerotherapy.     
Considering the variability of symptoms and disabilities caused by VMs as well as the 
individual opinion and experience of each patient, general treatment strategies 
applicable to all VMs are impossible to establish. The treatment options must be 
carefully discussed with each patient and the complication risk weighed against the 
subjective symptoms and expected benefit from the treatment.  
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6.4 Potential limitations of the study (I-IV) 
 
This study was limited by the retrospective study design. Any measurement of 
subjective symptoms and disabilities was difficult based on the patient records only, not 
allowing us to reliably report the sclerotherapy outcomes (I,III,IV). We hence used the 
need for secondary surgery as an end variable (I). The patient number was relatively 
low, especially for the comparison of the safety of different sclerosants (III, IV) and 
hemostatic variables in different diagnostic subgroups (II). The sclerotherapy setting is 
highly variable depending on the individual features of each patient and malformation. 
Consequently, the treatment outcome and complication risk are influenced by numerous 
unstandardized factors in addition to those analyzed here (III, IV).  
 
6.5 Future prospects 
 
This research raised many further questions to be answered: 
- Although now better able to differentiate ASTs from common VMs, 
the optimal treatment option for these often very symptomatic patients 
remains unclear. Prospective evaluations of long-term outcomes of 
surgical treatment would be valuable. 
- As AST lesions closely resemble PHOSTs by histology, genetic 
studies evaluating PTEN mutations both locally from AST lesions and 
systemically from the blood of these patients, could help to establish 
the connection between AST and PHOST. 
- According to our unpublished preliminary data, the profiles of 
coagulation biomarkers differ between AST and VM patients. This 
finding requires confirmation with a larger study population.  
- Ongoing research on the specific effects of genetic mutations will 
further elucidate the pathophysiology of VMs and the co-regulation of 




Our research suggests that many intramuscular vascular lesions diagnosed as VMs but 
with unsatisfactory sclerotherapy outcome are not VMs by histology but are instead 
compatible with another distinct entity, designated as AST (I).  
We found novel associations between coagulation biomarkers and VMs that are not 
explained by the prevailing theory of increased consumption, but reinforce the idea of a 
close relationship between coagulation and angiogenesis (II).  
Superficial lesion location and use of ethanol are predisposing factors for sclerotherapy 
complications, most of which are local and conservatively manageable (III). Extensive 
morphology, critical locations, and blood coagulopathy are associated with severe, 
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